Nodus Oncology

Executive Summary

Nodus Oncology is a UK-based preclinical biotech developing next-generation precision medicines that target metabolic vulnerabilities in cancer driven by genomic instability and replication stress. The company's lead programs are first- and best-in-class small molecule inhibitors of DNA damage and replication stress response pathways. By exploiting these tumor-specific weaknesses, Nodus aims to achieve selective cancer cell killing while sparing normal tissues. With no disclosed pipeline details, the company is likely in lead optimization or IND-enabling studies, positioning for key milestones in the next 12-18 months.

Upcoming Catalysts (preview)

• Q4 2026IND/CTA submission for lead candidate40% success
• Q2 2027Presentation of preclinical efficacy data at major conference (e.g., AACR, ASCO)60% success
• TBDPotential partnership or licensing deal for pipeline asset30% success